A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Phase 3Recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 500 (estimated)
- Start date
- 22 Jan 2026
- Primary completion
- Feb 2031 (estimated)
- Study completion
- 1 Nov 2031
- Last update posted
- 28 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Sonrotoclax Drug
- Zanubrutinib Drug
- Acalabrutinib Drug
- Venetoclax Drug
Conditions and primary outcome
- Chronic Lymphocytic Leukemia
Primary outcome
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC) (Up to approximately 70 months); Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4) (Up to approximately 16 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07277231.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07277231 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.